Published in TB and Outbreaks Week, January 4th, 2005
The grants will fund preclinical development of the company's West Nile virus and dengue vaccines and a significant portion of the Phase I human clinical trial for the dengue vaccine. These grants bring total federal funding for Hawaii Biotech's Emerging Disease/Bioterrorism program to over $31 million, including $12 million in Department of Defense and NIH anthrax funding as well as smaller federally funded projects in ebola, malaria and tick-borne encephalitis. The company also has a self-funded flu program.
"Our goal is to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.